Autoimmunity in the elderly: Implications for cancer

Journal of Cancer Research and Therapeutics

Volumn 8, Issue 4, 2012, Pages 520-527

  Malaguarnera, Michele ^a   Cristaldi, Erika ^a   Romano, Giulia ^a   Malaguarnera, Lucia ^b  

^a CANNIZZARO HOSPITAL   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

Autoimmunity; cancer; elderly; lymphoma; Th17 cells; treg cells

Indexed keywords

INTERLEUKIN 4; INTERLEUKIN 5; TRANSCRIPTION FACTOR FOXP3;

AGING; APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CELL DEATH; CHRONIC INFLAMMATION; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSURVEILLANCE; MEMORY T LYMPHOCYTE; NEOPLASM; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; RISK FACTOR; SENESCENCE; TH17 CELL; TH2 CELL; TUMOR IMMUNITY; TUMOR IMMUNOLOGY;

AGED; AGED, 80 AND OVER; AGING; ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84875525032     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.106527     Document Type: Review

References (75)

1. Spaulding C, Guo W, Effros RB. Resistance to apoptosis in human CD8+ T cells that reach replicative senescence after multiple rounds of antigen-specific proliferation. Exp Gerontol 1999;34:633-44.
2. Malaguarnera L, Ferlito L, Di Mauro S, Imbesi RM, Scalia G, Malaguarnera M. Immunosenescence and cancer: A review. Arch Gerontol Geriatr 2001;32:77-93.
3. Boren E, Gershwin ME. Inflamm-aging: Autoimmunity, and the immune-risk phenotype. Autoimmun Rev 2004;3:401-6.
4. Pawelec G, Adibzadeh M, Pohla H, Schaudt K. Immunosenescence: Aging of the immune system. Immunol Today 1995;16:420-2.
5. Malaguarnera L, Cristaldi E, Lipari H, Malaguarnera M. Acquired immunity: Immunosenescence and physical activity. Eur Rev Aging Phys Act 2008;5:61-8.
6. Looney RJ, Falsey A, Campbell D, Torres A, Kolassa J, Brower C, et al. Role of cytomegalovirus in the T cell changes seen in elderly individuals. Clin Immunol 1999;90:213-9.
7. Globerson A, Effros R. Aging of lymphocytes and lymphocytes in the aged. Immunol Today 2000;21:515-21.
8. Yen JH, Moore BE, Nakajima T, Scholl D, Schaid DJ, Weyand CM, et al. Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J Exp Med 2001;193:1159-67.
9. Schirmer M, Vallejo AN, Weyand CM, Goronzy JJ. Resistance to apoptosis and elevated expression of Bcl-2 in clonally expanded CD4+CD28-T cells from rheumatoid arthritis patients. J Immunol 1998;161:1018-25.
10. Malaguarnera L, Cristaldi E, Vinci M, Malaguarnera M. The role of exercise on the innate immunity of the elderly. Eur Rev Aging Phys Act 2008;5:43-9.
11. Haynes L, Eaton SM, Swain SL. The defects in effector generation associated with aging can be reversed by addition IL-2 but not other related gamma-c receptor binding cytokines. Vaccine 1999;18: 1649-53.
12. van Arkel C, Nooij FJ, van der Sluijs-Gelling AJ, Radl J. Frequency of clonal dominance in the specific antibody response to DNP-HSA in CBA and C57BL mice reflects their susceptibility to age-associated development of monoclonal gammopathies. Clin Immunol Immunopathol 1997;83:272-80.
13. Ioannidis JPA, Katsifis GE, Stavropoulos ED, Manoussakis MN, Moutsopoulos HM. Evaluation of the association of autoantibodies with mortality in the very elderly: A cohort study. Rheumatology 2003;42:357-61.
14. Tomer Y, Sherer Y, Shoenfeld Y. Autoantibodies, autoimmunity and cancer. Oncol Rep 1998;5:753-61.
15. Gordon J, Rosenthal M. Failure to detect age-related increase of nonpathological autoantibodies. Lancet 1984;1:231.
16. Ramos-Casals M, Garcia-Carrasco M, Brito MP, Lopez-Soto A, Font J. Autoimmunity and geriatrics: Clinical significance of autoimmune manifestations in the elderly. Lupus 2003;12:341-55.
17. Newkirk MM. Rheumatoid factors: Host resistance or autoimmunity Clin Immunol 2002;104:1-13.
18. Iakoubov LZ, Torchilin VP. A novel class of antitumour antibodies: Nucleosome-restricted antinuclear autoantibodies (ANA) from healthy aged non autoimmune mice. Oncol Res 1997;9:439-46.
19. Nashitz JE, Rosner I, Rozenbaum M, Elias N, Yeshurun D. Cancerassociated rheumatic disorders: Clues to occult neoplasia. Semin Arthritis Rheum 1995;24:231-41.
20. Fields RA, Toubbeh H, Searles RP, Bankhurst AD. The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies. J Rheumatol 1989;16:623-5.
21. Hasler P, Zouali M. Immune receptor signalling, aging, and autoimmunity. Cell Immunol 2005;233:102-8.
22. Stacy S, Krolick KA, Infante AJ, Kraig E. Immunological memory and late onset autoimmunity. Mech Ageing Dev 2002;123:975-85.
23. Hueber W, Kidd BA, Tomooka BH, Lee BJ, Bruce B, Flies JF, et al. Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis Rheum 2005;52:2645-55.
24. Motta M, Ferlito L, Malaguarnera L, Vinci E, Bosco S, Maugeri D, et al. Alterations of lymphocytic set-up in elderly patients with cancer. Arch Gerontol Geriatr 2003;36:7-14.
25. Fasth AE, Cao D, van Vollenhoven R, Trollmo C, Malmstrom V. CD28 CD4 T cells-characterization of an effector memory T-cell population in patients with rheumatoid arthritis. Scand J Immunol 2004;60:199-208.
26. Malaguarnera L, Cristaldi E, Malaguarnera M. The role of immunity in elderly cancer. Crit Rev Oncol Hematol 2010;74:40-60.
27. Pawlik A, Ostanek L, Brzosko I, Brzosko M, Masiuk M, Machalinski B, et al. The expansion of CD4+CD28 T cells in patients with rheumatoid arthritis. Arthritis Res Ther 2003;5:210-3.
28. Goronzy JJ, Weyand CM. Aging, autoimmunity and arthritis: T-cell senescence and contraction of T-cell repertoire diversity-catalysts of autoimmunity and chronic inflammation. Arthritis Res Ther 2003;5:225-34.
29. Gupta S. Tumour necrosis factor-alpha-induced apoptosis in T cells from aged humans: A role of TNFR-I and downstream signaling molecules. Exp Gerontol 2002;37:293-9.
30. Hsu HC, Mountz JD. Origin of late-onset autoimmune disease. Immunol Allergy Clin North Am 2003;23:65-82.
31. Potestio M, Caruso C, Gervasi F, Scialabba G, D'Anna C, Di Lorenzo G, et al. Apoptosis and aging. Mech Ageing Dev 1998;102:221-37.
32. Lio D, D'Anna C, Scola L, Di Lorenzo G, Colombo A, List̀ F, et al. Interleukin-5 production by mononuclear cells from aged individuals: Implication for autoimmunity. Mech Ageing Dev 1999;106:297-304.
33. Candore G, Romano CG, D'Anna C, Di Lorenzo G, Gervasi F, Lio D, et al. Biological basis of the HLA-B8,DR3 associated progression of acquired immune deficiency virus syndrome. Pathobiology 1998;66:33-7.
34. Segal R, Dayan M, Zinger H, Habut B, Shearer GM, Mozes E. The effect of IL-12 on clinical and laboratory aspects of experimental SLE in young and aging mice. Exp Gerontol 2003;38:661-8.
35. Weyand CM, Fulbright JW, Goronzy JJ. Immunosenescence, autoimmunity, and rheumatoid arthritis. Exp Gerontol 2003;38:833-41.
36. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
37. Conrad K. Autoantibodies in cancer patients and in persons with a higher risk of cancer development. In: Shoenfeld Y, Gershwin MF, editors. Cancer and autoimmunity. The Netherlands: Elsevier; 2000. p. 159-74.
38. Schved JF, Dupuy-Fons C, Biron C, Quere I, Janbon C. A prospective epidemiological study on the occurrence of antiphospholipid antibody: The Montpellier Antiphospholipid (MAP) Study. Haemostasis 1994;24:175-82.
39. Godfrey T, D'Cruz D. Antiphospholipid syndrome: General features. In: Khamashta MA editors. Hughes Syndrome. Antiphospholipid Syndrome. London: Springer; 2000. p. 8-19.
40. Ramos-Casals M, Brito-Zeron P, Lopez-Soto A, Font J. Systemic autoimmune diseases in elderly patients: Atypical presentation and association with neoplasia. Autoimmun Rev 2004;3:376-82.
41. Callen JP. Relation between dermatomyositis and polymyositis and cancer. Lancet 2001;357:85-6.
42. Zhang W, Jiang SP, Huang L. Dermatomyositis and malignancy: A retrospective study of 115 cases. Eur Rev Med Pharmacol Sci 2009;13:77-80.
43. National Cancer Institute-SEER Cancer Statistics Review 1975-2005.
44. Gatling RR. Prostate carcinoma: An autopsy evaluation of the influence of age, tumour grade and therapy on tumour biology. South Med J 1990;83:782-4.
45. Torchilin VP, Iakoubov LZ, Estrov Z. Antinuclear autoantibodies as potential antineoplastic agents. Trends Immunology 2001;22:424-7.
46. Dighiero G. Autoimmunity and B-cell malignancies. Hematol Cell Ther 1998;40:1-9.
47. Houghton AN. Cancer antigens: Immune recognition of self and altered self. J Exp Med 1994;180:1-4.
48. Chakravarty E, Genovese MC. Rheumatic syndromes associated with malignancy. Curr Opin Rheumatol 2003;15:35-43.
49. Abu-shakra M, Guillemin F, Lee P. Cancer in systemic sclerosis. Arthritis Rheum 1993;36:460-7.
50. Lourenco EV, La Cava A. Natural regulatory T cells in autoimmunity. Autoimmunity 2011;44:32-42.
51. Askenasy N, Kaminitz A, Yarkoni S. Mechanisms of T regulatory cell function. Autoimmun Rev 2008;7:370-5.
52. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-61.
53. Wan YY, Flavell RA. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 2007;15:766-70.
54. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4 + CD25 + regulatory T cells. Nat Immunol 2003;4:330-6.
55. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: Moving beyond current vaccines. Nat Med 2004;10:909-15.
56. Jones E, Dahm-Vicker M, Simon AK, Green A, Powrie F, Cerundolo V, et al. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun 2002;2:1.
57. Loddenkemper C, Hoffmann C, Stanke J, Nagorsen D, Baron U, Olek S, et al. Regulatory (FOXP3+) T cells as target for immune therapy of cervical intraepithelial neoplasia and cervical cancer. Cancer Sci 2009;100:1112-7.
58. Viguier M, Lemaître F, Verola O, Cho MS, Gorochov G, Dubertret L, et al. Foxp3 expressing CD4+CD25 (high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004;173:1444-53.
59. Imai H, Saio M, Nonaka K, Suwa T, Umemura N, Ouyang GF, et al. Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumour immunity in a mouse model of colon adenocarcinoma. Cancer Sci 2007;98:416-23.
60. Ko K, Yamazaki S, Nakamura K, Nishioka T, Hirota K, Yamaguchi T, et al. Treatment of advanced tumours with agonistic anti-GITR mAb and its effects on tumour-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med 2005;202:885-91.
61. Han GM, Zhao B, Jeyaseelan S, Feng JM. Age-associated parallel increase of Foxp3+CD4+ regulatory and CD44+CD4+ memory T cells in SJL/J mice. Cell Immunol 2009;258:188-196.
62. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumour lymphocytes. Science 2002;298:850-4.
63. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001;411:380-4.
64. von Herrath MG, Harrison LC. Antigen-induced regulatory T cells in autoimmunity. Nat Rev Immunol 2003;3:223-32.
65. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumour immunity by removing CD25+ CD4+ T cells: A common basis between tumour immunity and autoimmunity. J Immunol 1999;163:5211-8.
66. Eggena MP, Walker LS, Nagabhushanam V, Barron L, Chodos A, Abbas AK. Cooperative roles of CTLA-4 and regulatory T cells in tolerance to an islet cell antigen. J Exp Med 2004;199:1725-30.
67. Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of T(H)17 cells. Nature 2008;453:1051-7.
68. Jin D, Zhang L, Zheng J, Zhao Y. The inflammatory Th 17 subset in immunity against self and non-self antigens. Autoimmunity 2008;41:154-162.
69. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, et al. Tumour-specific Th17-polarized cells eradicate large established melanoma. Blood 2008;112:362-73.
70. Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, et al. Phase I/II trial of Tremelimumab in patients with metastatic melanoma. J Clin Oncol 2009;27:1075-81.
71. von Euw E, Chodon T, Attar N, Jalil J, Koya RC, Comin-Anduix B, et al. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med 2009;7:35.
72. Nakae S, Iwakura Y, Suto H, Galli SJ. Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J Leukoc Biol 2007;81:1258-68.
73. Zhou M, Yang B, Ma R, Wu C. Memory Th-17 cells specific for C. albicans are persistent in human peripheral blood. Immunol Lett 2008;118:72-81.
74. Keler T, Halk E, Vitale L, O'Neill T, Blanset D, Lee S, et al. Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. J Immunol 2003;171:6251-9.
75. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3:541-7.